[go: up one dir, main page]

CY1111660T1 - Χρηση παραγωγων θειενοπυριδονης ως ενεργοποιητες αμρκ και φαρμακευτικες συνθεσεις που τις περιεχουν - Google Patents

Χρηση παραγωγων θειενοπυριδονης ως ενεργοποιητες αμρκ και φαρμακευτικες συνθεσεις που τις περιεχουν

Info

Publication number
CY1111660T1
CY1111660T1 CY20111100285T CY111100285T CY1111660T1 CY 1111660 T1 CY1111660 T1 CY 1111660T1 CY 20111100285 T CY20111100285 T CY 20111100285T CY 111100285 T CY111100285 T CY 111100285T CY 1111660 T1 CY1111660 T1 CY 1111660T1
Authority
CY
Cyprus
Prior art keywords
amrk
thienopyridones
producers
activators
pharmaceutical compositions
Prior art date
Application number
CY20111100285T
Other languages
English (en)
Inventor
Sophie Hallakou-Bozec
Christine Charon
Bjoern Hock
Oliver Poeschke
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CY1111660T1 publication Critical patent/CY1111660T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Χρήση των παραγώγων θειενοπυριδόνης του τύπου (I), όπου τα Β, R, R6, Υ και Ζ έχουν όπως ορίζεται στην περιγραφή, και των φαρμακευτικά αποδεκτών αλάτων τους, για την παρασκευή μιας φαρμακευτικής σύνθεσης η οποία είναι χρήσιμη στη θεραπευτική αντιμετώπιση του διαβήτη, του μεταβολικού συνδρόμου, συγγενών διαταραχών και της παχυσαρκίας.
CY20111100285T 2005-08-18 2011-03-14 Χρηση παραγωγων θειενοπυριδονης ως ενεργοποιητες αμρκ και φαρμακευτικες συνθεσεις που τις περιεχουν CY1111660T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05291753A EP1754483A1 (en) 2005-08-18 2005-08-18 Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
EP06762350A EP1915150B1 (en) 2005-08-18 2006-07-03 Use of thienopyridone derivatives as ampk activators and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
CY1111660T1 true CY1111660T1 (el) 2015-10-07

Family

ID=35636709

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100285T CY1111660T1 (el) 2005-08-18 2011-03-14 Χρηση παραγωγων θειενοπυριδονης ως ενεργοποιητες αμρκ και φαρμακευτικες συνθεσεις που τις περιεχουν

Country Status (20)

Country Link
US (1) US20090105293A1 (el)
EP (2) EP1754483A1 (el)
JP (1) JP5161774B2 (el)
KR (1) KR20080034491A (el)
CN (1) CN101232883A (el)
AT (1) ATE496622T1 (el)
AU (1) AU2006281761B2 (el)
BR (1) BRPI0614828A2 (el)
CA (1) CA2619505C (el)
CY (1) CY1111660T1 (el)
DE (1) DE602006019880D1 (el)
DK (1) DK1915150T3 (el)
ES (1) ES2359860T3 (el)
MX (1) MX2008002062A (el)
PL (1) PL1915150T3 (el)
PT (1) PT1915150E (el)
RU (1) RU2416409C2 (el)
SI (1) SI1915150T1 (el)
WO (1) WO2007019914A1 (el)
ZA (1) ZA200802454B (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005017152B4 (de) * 2005-04-13 2007-02-08 Lindauer Dornier Gmbh Verfahren zum Trocknen von vorzugsweise plattenförmigen Produkten und Durchlauftrockner in Mehretagenbauweise
CN101854933A (zh) 2007-09-10 2010-10-06 钙医学公司 调节细胞内钙的化合物
HRP20160907T1 (hr) * 2008-04-11 2016-09-23 Merck Patent Gmbh Derivati tienopiridona kao aktivatori amp-aktivirane protein kinaze (ampk)
NZ589690A (en) * 2008-05-05 2012-07-27 Merck Patent Gmbh Thienopyridone derivatives as AMP-activated protein kinase (AMPK) activators
GB0813403D0 (en) 2008-07-22 2008-08-27 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
CA2734500A1 (en) * 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010103040A1 (en) 2009-03-10 2010-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) 5'-adenosine monophosphate-activated protein kinase (ampk) activators for treating pulmonary hypertension
KR101062670B1 (ko) * 2009-06-01 2011-09-06 (주)아모레퍼시픽 2,5-비스-아릴-3,4-디메틸테트라하이드로퓨란 리그난을 유효성분으로 포함하는 에이엠피케이의 활성화에 의해 매개되는 비만 관련 질환의 예방 또는 치료용 조성물
WO2011034962A2 (en) 2009-09-16 2011-03-24 Calcimedica Inc. Compounds that modulate intracellular calcium
CN102666485A (zh) * 2009-09-21 2012-09-12 霍夫曼-拉罗奇有限公司 烯烃羟吲哚衍生物及其用于治疗肥胖症，糖尿病和高脂血症的应用
EP2552435A1 (en) 2010-04-02 2013-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
MX337711B (es) 2010-08-27 2016-03-15 Calcimedica Inc Compuestos que modulan el calcio intracelular.
CN103189376B (zh) 2010-09-01 2016-02-24 拜耳知识产权有限责任公司 具有除草活性的酮基磺内酰胺和二酮基吡啶
US9005909B2 (en) 2011-01-06 2015-04-14 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring AMPK activation
EP2683690A1 (en) * 2011-03-07 2014-01-15 GlaxoSmithKline LLC Quinolinone derivatives
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
WO2015103480A1 (en) 2014-01-02 2015-07-09 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
CN105315275B (zh) * 2014-07-14 2019-10-01 中国科学院上海药物研究所 一类吡唑酮化合物及其用途
US20190054096A1 (en) 2015-09-30 2019-02-21 Instituto De Medicina Molecular Methods for attenuating parasite virulence
US20190350955A1 (en) 2016-06-30 2019-11-21 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods and pharmaceutical compositions for the treatment of cardiomyopathies
RU2766146C2 (ru) * 2016-10-05 2022-02-08 Юниверсити Оф Питтсбург - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Низкомолекулярные активаторы амфк
WO2018156459A1 (en) * 2017-02-22 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting emt pathways to treat cancer, organ fibrosis and metabolic disorders
CN113166168A (zh) * 2018-11-16 2021-07-23 博希尔公司 噻吩并吡啶酮衍生物的一水合钾盐及其制备方法
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
EP4027987A4 (en) 2019-09-10 2023-11-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods and materials for increasing level of phosphorylated ampk protein
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds
EP4433458A4 (en) 2021-11-19 2025-10-29 Broad Inst Inc Bifunctional chimeric molecules for labeling kinases with target bond fractions and their methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358150A1 (fr) * 1976-07-13 1978-02-10 Parcor Nouvelles thieno (2,3-c) et (3,2-c) pyridines, leur procede de preparation et leur application
GB8625941D0 (en) * 1986-10-30 1986-12-03 Sandoz Ltd Substituted alpha-amino acids
DE4444815A1 (de) 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
FR2846656B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
JP2005089384A (ja) 2003-09-18 2005-04-07 Kao Corp 持久力向上剤

Also Published As

Publication number Publication date
JP5161774B2 (ja) 2013-03-13
PT1915150E (pt) 2011-05-02
ATE496622T1 (de) 2011-02-15
EP1915150B1 (en) 2011-01-26
CN101232883A (zh) 2008-07-30
ZA200802454B (en) 2009-01-28
SI1915150T1 (sl) 2011-04-29
ES2359860T3 (es) 2011-05-27
WO2007019914A1 (en) 2007-02-22
MX2008002062A (es) 2008-04-16
AU2006281761A1 (en) 2007-02-22
PL1915150T3 (pl) 2011-05-31
CA2619505A1 (en) 2007-02-22
DE602006019880D1 (de) 2011-03-10
DK1915150T3 (da) 2011-02-21
KR20080034491A (ko) 2008-04-21
RU2008109914A (ru) 2009-09-27
AU2006281761B2 (en) 2012-01-19
US20090105293A1 (en) 2009-04-23
RU2416409C2 (ru) 2011-04-20
EP1754483A1 (en) 2007-02-21
EP1915150A1 (en) 2008-04-30
CA2619505C (en) 2015-04-28
BRPI0614828A2 (pt) 2011-04-19
JP2009504693A (ja) 2009-02-05

Similar Documents

Publication Publication Date Title
CY1111660T1 (el) Χρηση παραγωγων θειενοπυριδονης ως ενεργοποιητες αμρκ και φαρμακευτικες συνθεσεις που τις περιεχουν
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
MY149622A (en) Pyrazoles as 11-beta-hsd-1
NO20085067L (no) 4,5-difenyl-pyrimidinyl substituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
CY1110952T1 (el) Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3
CY1112727T1 (el) Παραγωγα κυκλοβουτυλ αμινης βενζοθειαζολης και η χρηση αυτων ως προσδετες των υποδοχεων ισταμινης-3
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
PL2114933T3 (pl) Piperydyny jako agoniści GPCR
NO20076418L (no) Heterocyclic compounds as agonists for the thyroid receptor
ZA200700765B (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
MY136034A (en) New medicaments for the treatment of chronic obstructive pulmonary disease
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
ATE530519T1 (de) Cyclobutylaminderivate
MX2007012212A (es) 1h-pirazol 4-carboxilamidas, su preparacion y su uso como 11-beta-hidroxiesteroide deshidrogenasa.
TW200806311A (en) Neuropeptide-2 receptor-agonists
PA8531701A1 (es) Derivados de pirimidina
NO20070974L (no) Substituerte N-acyl-2-aminotiazoler
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
IL229594A (en) Derived Lactone Derivatives, Pharmaceutical Compositions Containing Them and Their Uses in the Preparation of Medical Preparations for Cancer Treatment
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
CY1111067T1 (el) Χρηση της ν-(διβενζ (β,f) οξεπιν-10-υλμεθυλ) -ν-μεθυλ-ν-προπ-2-υνυλαμινης (omigapil) στην προληψη και/ή την θεραπεια της μυϊκης δυστροφiας
ZA200706705B (en) Phenylbenzoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic uses thereof